Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP1189 in Polymyalgia Rheumatica Remission on Glucocorticoids
2026-525343-33-00Phase 2Authorised
- Sponsor
- SynAct Pharma AB
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in polymyalgia rheumatica (PMR) comparing AP1189 100 mg/day with Placebo (2 arms). Primary endpoint: Safety evaluations. Planned start Mar 2026; status: authorised.
02
Drugs
resomelagon
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on 2026-525343-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525343-33-00.